| Outcome Measures: |
Primary: 1. Change in the percentage of donor specific antibodies, We will check these donor specific antibodies to: HLA-A, -B and -C; or HLA-DR, -DQ and -DP. We will quantify the expression of these markers by Flow Cytometry analysis and reported as mean fluorescence intensity (MFI) units., Time of transplant and six months post-transplant|Changes in the percentage of blood immunologic markers, We will monitor the lymphocyte profile in blood in response to these 2 different treatments. The lymphocyte profile test will be performed by multi-parametric flow cytometry analysis with a panel of specific flourochrome-conjugated antibodies to selectively determine the following sub-populations: 1. Circulating T cells: CD4/CD8 rates and determine the following CD4 subpopulations: effector TH1, TH2, TH9, Tfh, and regulatory/suppressor T cells. 2. Circulating B cells (number and percentage of naïve, activated, memory and plasma B cells. 3. Circulating NK cells (mature and immature), Time of transplant and six months post-transplant | Secondary: Changes in creatinine clearance, Baseline creatinine will be considered the creatinine plasma levels several days after transplantation once the kidney function is stabilized., Time of transplant and six months post-transplant | Other: Changes in GFR, We will use the MDRD GFR equation to estimate glomerular filtration rate based on baseline creatinine and patient characteristics (age, gender and race), 30 Days post transplant and months 3 and 6
|
